N-甲基-3-氨基苯磺酰胺 | 459434-40-3

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基-3-氨基苯磺酰胺
• 中文别名: 3-氨基-n-甲基苯磺酰胺
• 英文名称: 3-amino-N-methylbenzenesulfonamide
• 英文别名: N-methyl 3-aminobenzenesulfonamide
• CAS: 459434-40-3
• 化学式: C₇H₁₀N₂O₂S
• mdl: MFCD07363815
• 分子量: 186.235
• InChiKey: SFCWILLFDXUKRB-UHFFFAOYSA-N

物化性质

• 沸点：
  375.7±44.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下保存，避光且保持干燥和密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methyl 3-Aminobenzenesulfonamide
Synonyms: 3-Amino-N-methylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl 3-Aminobenzenesulfonamide
CAS number: 459434-40-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2S
Molecular weight: 186.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲基-3-氨基苯磺酰胺 在 bis(tri-tert-butylphosphine)palladium(0) 、 silver trifluoromethanesulfonate sodium carbonate 作用下， 以 1,4-二氧六环 、 水 、 异丙醇 为溶剂， 反应 1.75h， 生成 N-methyl-3-{[6-(4-pyridinyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzenesulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS
  [FR] COMPOSÉS ET PROCÉDÉS

  摘要：

  揭示了具有化学式（I）的化合物，其中X、Y、Z、R1、R2和R3如本文所定义，并公开了制备和使用这些化合物的方法。

  公开号：

  WO2011149827A1
• 作为产物：
  描述：

  3-硝基苯磺酰氯 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 生成 N-甲基-3-氨基苯磺酰胺
  参考文献：
  名称：

  新型3-（喹啉-4-基氨基）苯磺酰胺作为碳酸酐酶同工型I和II抑制剂的合成及生物学评价

  摘要：

  抽象的 碳酸酐酶（CAs，EC 4.2.1.1）是涉及多种生物过程的关键金属酶。我们报告了合成和生物学评估的新系列的苯磺酰胺结合未/取代的乙基喹啉-3-羧酸酯部分。新合成的化合物在体外评估为胞质人（h）亚型hCA I和II的抑制剂。此处报道的喹啉在不同程度上均抑制了hCA I和II亚型：h CA I在0.966–9.091μM范围内被K I s抑制，而hCA II在0.083–3.594μM范围内被抑制。主7-氯-6- flouro取代sulphfonamide衍生物6E（ķ我 = 0.083μM）被证明是抑制hCA II活性最强的喹啉，而其次磺酰胺类似物未能抑制hCA II直至10μM，从而证实了主要的磺酰胺类作为锌结合基团的关键作用。 CA抑制活性。

  DOI：

  10.1080/14756366.2019.1652282

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013096153A1

  公开（公告）日：2013-06-27

  The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代喹啉衍生物。具体而言，本发明涉及根据公式I的化合物：其中R，R1，R2，R3和R4按如下定义。本发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢有关的疾病，例如癌症，更具体地说是乳腺癌、结肠癌、前列腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗与之相关的疾病的方法。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors
  作者：Bin Tan、Xiaomeng Zhang、Xu Quan、Guochuang Zheng、Xue Li、Liwen Zhao、Wei Li、Bo Li

  DOI：10.1016/j.bmcl.2020.127339

  日期：2020.8

  ol-4-yl) oxy) pyridine-2-yl) amino derivatives as ALK5 inhibitors. The optimization led to identification of potent and selective ALK5 inhibitors 12r. The compound 12r exhibited strong inhibitory activity both in vitro and in vivo, and pharmacokinetics study showed an oral bioavailability of 57.6%. Thus, compound 12r may provide as new therapeutic option as ALK5 TGF-βR1 inhibitor.

  TGF-βI型受体（也称为激活素样激酶5或ALK5）在纤维化疾病的发展以及肿瘤的侵袭和转移中也起着至关重要的作用。靶向ALK5的小抑制剂的开发已被证实是纤维化疾病和癌症的潜在治疗策略。在这里，我们开发了各种作为ALK5抑制剂的4-（（1-环丙基-3-（四氢-2 H-吡喃-4-基）-1 H-吡唑-4-基）氧基）吡啶-2-基）氨基衍生物。优化导致了有效和选择性ALK5抑制剂12r的鉴定。化合物12r在体外和体内均表现出强大的抑制活性和药代动力学研究显示，口服生物利用度为57.6％。因此，化合物12r可以作为ALK5TGF-βR1抑制剂提供新的治疗选择。
• TGF-βR1抑制剂及其应用
  申请人：南京圣和药业股份有限公司

  公开号：CN111196804A

  公开（公告）日：2020-05-26

  本发明属于医药化学领域，涉及一类作为TGF‑βR1抑制剂的化合物及其应用，具体地，本发明提供式I所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗和/或预防TGF‑βR1相关疾病，例如癌症、组织增生类疾病、纤维化和炎性疾病等类疾病的用途。本发明的化合物对TGF‑βR1激酶表现出了显著的抑制活性，非常有希望成为TGF‑βR1相关疾病的治疗剂。